Galena Biopharma Names New President and CEO

From DCAT Value Chain Insights (VCI)

By People On The Move posted 08-28-2014 18:06

Galena Biopharma, Inc. a biopharmaceutical company based in Portland, Oregon, has appointed Mark W. Schwartz, PhD, as president and chief executive officer (CEO). Schwartz was previously Galena's executive vice president and chief operating officer. He replaces Mark J. Ahn, who resigned as the president and CEO and as a director of the company to pursue other personal and professional goals. It is expected that Schwartz will also be appointed to Galena's board of directors.

​Schwartz brings more than 30 years of experience in the biotechnology and life science industry and was appointed executive vice president and chief operating officer in 2011 following Galena's acquisition of Apthera, Inc. where he served as the company's president and CEO. Prior to Apthera, Schwartz served for five years as president and CEO of Bayhill Therapeutics, a company developing an innovative DNA vaccine platform for the treatment of autoimmune diseases where he completed a successful partnership with Genentech for the development of the company's Type 1 diabetes vaccine. He had also served as president and CEO of Calyx Therapeutics. Earlier in his career, he held a range of positions in R&D, marketing, sales, business development and executive management at Trega BioSciences, Incyte Genomics, Synteni, Tripos Inc., Applied Biosystems and DuPont Diagnostics.

Source: Galena Biopharma


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription